Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11111473 | 0.87 | SMN1; SMN2 (0.59) | SMN1; SMN2CA14ALDH1A1CA12KMT2A | |
| SCHEMBL11648465 | 0.86 | SMN1; SMN2 (0.48) | SMN1; SMN2CA14ALDH1A1CA12CYP3A4 | |
| SCHEMBL11422036 | 0.84 | SMN1; SMN2 (0.60) | SMN1; SMN2CA14ALDH1A1CA12CYP3A4 | |
| SCHEMBL856080 | 0.82 | SMN1; SMN2 (0.61) | SMN1; SMN2CA14ALDH1A1CA12CYP3A4 | |
| SCHEMBL13220417 | 0.82 | SMN1; SMN2 (0.54) | SMN1; SMN2CA14ALDH1A1CA12CYP3A4 | |
| SCHEMBL2855909 | 0.81 | SMN1; SMN2 (0.57) | SMN1; SMN2CA14ALDH1A1CA12CYP3A4 | |
| SCHEMBL4610375 | 0.81 | SMN1; SMN2 (0.48) | SMN1; SMN2CA14ALDH1A1CA12CYP3A4 | |
| SCHEMBL17953987 | 0.79 | SMN1; SMN2 (0.44) | SMN1; SMN2CA14ALDH1A1CA12CYP3A4 | |
| SCHEMBL12873399 | 0.79 | SMN1; SMN2 (0.44) | SMN1; SMN2CA14ALDH1A1CA12CYP3A4 | |
| SCHEMBL5799030 | 0.78 | SMN1; SMN2 (0.56) | SMN1; SMN2CA14ALDH1A1CA12CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130245286-A1 | PROCESS FOR PRODUCING WINE LACTONE | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-09-19 | — | — | US | disclosed |
| US-20130245286-A1 | PROCESS FOR PRODUCING WINE LACTONE | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-09-19 | — | — | US | disclosed |
| US-20130245287-A1 | PROCESS FOR PRODUCING WINE LACTONE | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-09-19 | — | — | US | disclosed |
| US-20130245287-A1 | PROCESS FOR PRODUCING WINE LACTONE | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-09-19 | — | — | US | disclosed |
| US-20130245287-A1 | PROCESS FOR PRODUCING WINE LACTONE | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-09-19 | — | — | US | disclosed |
| US-20130245286-A1 | PROCESS FOR PRODUCING WINE LACTONE | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-09-19 | — | — | US | disclosed |
| US-8481759-B2 | Process for producing wine lactone | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-07-09 | — | — | US | disclosed |
| US-8481759-B2 | Process for producing wine lactone | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-07-09 | — | — | US | disclosed |
| US-8481759-B2 | Process for producing wine lactone | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-07-09 | — | — | US | disclosed |
| US-20130030193-A1 | PROCESS FOR PRODUCING WINE LACTONE | TAKASAGO INTERNATIONAL CORPORATION | 2013-01-31 | — | — | US | disclosed |
| US-20130030193-A1 | PROCESS FOR PRODUCING WINE LACTONE | TAKASAGO INTERNATIONAL CORPORATION | 2013-01-31 | — | — | US | disclosed |
| US-20130030193-A1 | PROCESS FOR PRODUCING WINE LACTONE | TAKASAGO INTERNATIONAL CORPORATION | 2013-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130245286-A1 | PROCESS FOR PRODUCING WINE LACTONE | SUCLA2, ADH5, PCCA | SMN1; SMN2 3340/4885CA14 233/4885ALDH1A1 360/4885 |
| US-20130245287-A1 | PROCESS FOR PRODUCING WINE LACTONE | SUCLA2, ADH5, PCCA | SMN1; SMN2 3340/4885CA14 233/4885ALDH1A1 360/4885 |
| US-20130030193-A1 | PROCESS FOR PRODUCING WINE LACTONE | SUCLA2, ADH5, PCCA | SMN1; SMN2 3340/4885CA14 233/4885ALDH1A1 360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.